Working Group 1 

WG1 leader: Anita Milicic

WG1 vice-leaders: Ed Lavelle and Thorunn Olafsdottir

WG1 members can be found here.

Adjuvants for human and veterinary prophylactic vaccines

Adjuvants for prophylactic vaccines: At present a small number of adjuvants are approved for use in human prophylactic vaccines. Translating adjuvant innovation into novel human and veterinary vaccines has previously been a lengthy and complicated process. However, with recent clarification of the guidelines for adjuvanted vaccine licensure, the use of adjuvants will rapidly expand. For a growing number of diseases e.g. tuberculosis and malaria, novel adjuvants appear to be essential to confer adequate protection from infection and/or disease. Improving existing vaccines using novel adjuvants and developing a capacity for responding to new epidemics/pandemics is of key importance. Veterinary vaccines share a common goal with human vaccines. Importantly, veterinary vaccines increase cost effectiveness of livestock production methods, improve animal welfare, and play a key role in preventing human infections by animal-derived pathogens (including zoonoses and pandemics). Veterinary vaccines often have suboptimal efficacy or induce only short-term protection, calling for repeated immunisations. Furthermore, the cost effectivity of veterinary vaccination is a key factor, and drives the need for low-cost vaccines where adjuvants can likely play a significant role.



Published Oct. 19, 2017 12:39 PM - Last modified Mar. 15, 2018 2:41 PM